Pfizer Inc. $PFE Shares Sold by Blake Schutter Theil Wealth Advisors LLC

Blake Schutter Theil Wealth Advisors LLC lowered its stake in shares of Pfizer Inc. (NYSE:PFE) by 9.1% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 12,415 shares of the biopharmaceutical company’s stock after selling 1,239 shares during the period. Blake Schutter Theil Wealth Advisors LLC’s holdings in Pfizer were worth $301,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. GKV Capital Management Co. Inc. purchased a new position in Pfizer during the first quarter worth about $27,000. Curio Wealth LLC lifted its position in Pfizer by 36,600.0% during the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 1,098 shares during the period. Bayforest Capital Ltd purchased a new position in Pfizer during the first quarter worth about $28,000. North Capital Inc. purchased a new position in Pfizer during the first quarter worth about $28,000. Finally, Harbor Asset Planning Inc. purchased a new position in Pfizer during the second quarter worth about $29,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

PFE has been the topic of several recent analyst reports. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research report on Saturday. Morgan Stanley reduced their target price on Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research report on Friday, October 10th. Bank of America raised their price objective on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Finally, Citigroup raised their price objective on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Pfizer presently has a consensus rating of “Hold” and a consensus price target of $28.13.

Pfizer Price Performance

Shares of NYSE PFE opened at $24.79 on Friday. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $29.17. The business has a 50 day moving average price of $24.87 and a two-hundred day moving average price of $24.18. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The firm has a market cap of $140.92 billion, a PE ratio of 13.18, a price-to-earnings-growth ratio of 0.82 and a beta of 0.55.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. During the same quarter last year, the firm earned $0.60 EPS. Pfizer’s quarterly revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be given a $0.43 dividend. The ex-dividend date is Friday, November 7th. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. Pfizer’s dividend payout ratio (DPR) is presently 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.